anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A process for separating high-purity liquiritin, debitterized glycyrrhizin and licorice total flavonoids from monoammonium glycyrrhizinate mother liquor paste comprises the following steps: (1) adding water to the monoammonium glycyrrhizinate mother liquor paste, adjusting pH, dissolving, performing column chromatography with No. 1 resin, eluting with water to obtain eluate, adjusting pH, performing column chromatography with No. 2 resin, eluting with water to obtain eluate, eluting with gradient diluted ethanol from No. 2 column, concentrating the eluate under reduced pressure, and drying to obtain crude liquiritin; adding 95% ethanol into the crude product for recrystallization, filtering, and drying to obtain high-purity liquiritin. (2) And (3) taking the standby eluent, passing through a 3# resin column, eluting with water, concentrating and drying the eluent to obtain the bitter-removed aspartame. (3) Regenerating resin columns 1#, 2# and 3# with 95% ethanol, collecting combined eluates, concentrating, and drying to obtain Glycyrrhrizae radix total flavone. The invention adopts the mother liquor paste after the mono-ammonium glycyrrhizinate as the raw material, combines the separation and purification to obtain three products, improves the comprehensive utilization rate of the raw material, has high product value, low cost and good reproducibility, and is suitable for industrial large-scale production.
The invention discloses inulin gel and application thereof in preparation of ionizing radiation injury protection medicines. Inulin is a hydrophilic, low-cost and in vivo degradable natural polysaccharide extracted from plants, and is a natural dietary fiber. Inulin gel can stay in intestinal tract for a long time, and its ionizing radiation injury protection application comprises protection application to ionizing radiation hematopoietic system injury and radioactive intestinal injury. The application route is selected from oral administration and clysis. The inulin gel comprises inulin and water, and the preparation process comprises sequentially dissolving, heating, and cooling. For protection against ionizing radiation damage, the timing of administration of inulin gel includes pre-irradiation, post-irradiation and a combination of pre-irradiation and post-irradiation. The oral inulin gel has obvious radiation protection effect on the whole body irradiation of 6.5Gy and the whole abdomen irradiation of 13Gy, and the effect is equivalent to that of a clinic radiation-resistant medicament amifostine.
NEW MATERIAL:A compound shown by the formula [X is sulfamoyl, or bis(beta- chloroethyl)amino; R is alkyl]. EXAMPLE:gamma-(p-Sulfamoylphenylureido)propyltriethoxylsilane. USE:A carcinostatic agent. Showing improved activity especially against Ehrlich ascites carcinoma, ascites carcinoma of Walker carcinosarcoma, etc. An antibacterial agent, and an antifungal agent. A disinfectant. A sanitary processing agent. Useful as a coating material for changing the surface state of paper, wood, fiber, etc. PREPARATION:A gamma-isocyanate propyltrialkoxysilane is reacted with a substituted anilide or its salt in a solvent such as benzene, chloroform, etc. at -70-120 deg.C to give a compound shown by the formula.
BACKGROUND: Three settings are required on a programmed intermittent epidural bolus (PIEB) pump for labor analgesia: the PIEB next bolus (PIEBnb), PIEB interval (PIEBi), and PIEB volume (PIEBv). The ideal settings for these parameters are still unknown. We hypothesized a mathematical modeling tool, response surface methodology (RSM), could estimate 3 PIEB pump parameters while balancing 3 clinically important patient outcomes simultaneously. The study objective was to use RSM to estimate PIEB settings (PIEBnb, PIEBi, and PIEBv) while maximizing maternal satisfaction, minimizing the need for clinician-administered boluses, and optimizing the ratio of delivered/requested patient-controlled epidural analgesia (PCEA) boluses simultaneously.
METHODS: With institutional ethics approval, a double-blind randomized trial was completed in a tertiary care labor and delivery center. Nulliparous, English-speaking American Society of Anesthesiologists (ASA) physical status II patients aged 18 to 45 years at full term, single gestation in vertex presentation, in spontaneous labor and ≤7 cm cervical dilation were included. Patients with comorbidities, contraindications to neuraxial analgesia, using chronic analgesics, <152 cm, or body mass index (BMI) >45 kg/m 2 were excluded. After informed consent, labor analgesia was initiated using 10 mL ropivacaine 0.2% with 10 µg/mL fentanyl solution and PCEA (volume 6 mL every 10 minutes). Patients were randomized to predetermined PIEB settings. RSM identified 3 pump settings that represented a stationary point that best maximized or minimized 3 outcomes simultaneously: PCEA ratio (a ratio closest to 1), clinician bolus (optimal is 0), and maternal satisfaction (visual analog scale, 0-100, ideal response is ≥90).
RESULTS: Of 287 potential participants, 192 did not meet inclusion criteria or declined to participate, and 26 were withdrawn, leaving 69 patients for study inclusion. Using RSM, the suggested PIEB settings for all the primary study outcomes were as follows: PIEBnb = 29.4 minutes, PIEBi = 59.8 minutes, and PIEBv = 6.2 mL. These PIEB settings corresponded to the following clinical outcomes: maternal satisfaction at 93.9%, PCEA ratio at 0.77, and need for clinician bolus at 0.29. The dermatome sensory score was between T10 and T5 in 89% of the patients. The median lowest Bromage score was 4.
CONCLUSIONS: This novel study used a mathematical model to estimate PIEB pump settings while simultaneously maximizing 3 clinical outcomes. Equally weighted clinical outcomes prevent maximal outcome optimization and may not reflect patient priorities. Future studies or quality improvement endeavors could use RSM methodology to estimate PIEB pump settings targeting optimal values for a single clinical outcome of determined importance to parturients.
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are prevalent mesenchymal tumours of the gastrointestinal tract, commonly exhibiting structural variations in KIT and PDGFRA genes. While the mutational profiling of somatic tumours is well described, the genes behind the susceptibility to develop GIST are not yet fully discovered. This study explores the genomic landscape of two primary GIST cases, aiming to identify shared germline pathogenic variants and shed light on potential key players in tumourigenesis.
METHODS: Two patients with distinct genotypically and phenotypically GISTs underwent germline whole genome sequencing. CNV and single nucleotide variant (SNV) analyses were performed.
RESULTS: Both patients harbouring low-risk GISTs with different mutations (PDGFRA and KIT) shared homozygous germline pathogenic deletions in both CFHR1 and CFHR3 genes. CNV analysis revealed additional shared pathogenic deletions in other genes such as SLC25A24. No particular pathogenic SNV shared by both patients was detected.
CONCLUSION: Our study provides new insights into germline variants that can be associated with the development of GISTs, namely, CFHR1 and CFHR3 deep deletions. Further functional validation is warranted to elucidate the precise contributions of identified germline mutations in GIST development.
Chronic suppurative otitis media (CSOM) is a neglected disease that afflicts 330 million people worldwide and is the most common cause of permanent hearing loss among children in the developing world. Previously, we discovered that outer hair cell (OHC) loss occurred in the basal turn of the cochlea and that macrophages are the major immune cells associated with OHC loss in CSOM. Macrophage-associated cytokines are upregulated. Specifically, CCL-2, an important member of the MCP family, is elevated over time following middle ear infection. CCR2 is a common receptor of the MCP family and the unique receptor of CCL2. CCR2 knockout mice (CCR2-/-) have been used extensively in studies of monocyte activation in neurodegenerative diseases. In the present study, we investigated the effect of CCR2 deletion on the cochlear immune response and OHC survival in CSOM. The OHC survival rate was 84 ± 12.5% in the basal turn of CCR2+/+ CSOM cochleae, compared with was 63 ± 19.9% in the basal turn of CCR2-/- CSOM cochleae (p ≤ 0.05). Macrophage numbers were significantly reduced in CCR2-/- CSOM cochleae compared with CCR2+/+ CSOM cochleae (p ≤ 0.001). In addition, CCL7 was upregulated, whereas IL-33 was downregulated, in CCR2-/- CSOM cochleae. Finally, the permeability of the blood-labyrinth barrier in the stria vascularis remained unchanged in CCR2-/- CSOM compared with CCR2+/+ CSOM. Taken together, the data suggest that CCR2 plays a protective role through cochlear macrophages in the CSOM cochlea.
Bone quality is one of the major factors influencing the dental implant survival rate. Bone quality is believed to have effects on initial implant stability and success of osseointegration. Different implant designs and surgical protocols were developed for improving the survival rate in different bone quality. Although bone quality can be partly diagnosed by radiographic images, lots of experienced surgeons also evaluate bone quality with tactile sensation when they drill the bone. However, variations in evaluation of bone density maybe exist among different surgeons. The drilling speed also may have effect on the outcome of evaluation. For less experienced dentists, it is difficult to diagnose bone quality with tactile sensation in the beginning. The purpose of this study is to find proper drilling speed to classify bone quality by tactile sensation on a saw bone model. Saw bones of variant densities are used as training \& testing materials. The proper drilling speed to distinguish different bone quality will be evaluated and offered to junior dentists for better implant treatment outcome.
Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to Eplontersen administered subcutaneously once every 4 weeks until the end of study.
PCT No. PCT/EP93/00657 Sec. 371 Date Sep. 23, 1994 Sec. 102(e) Date Sep. 23, 1994 PCT Filed Mar. 18, 1993 PCT Pub. No. WO93/19724 PCT Pub. Date Oct. 14, 1993.A process for reducing the content of free formaldehyde and formic acid in nonionic and anionic surfactants is provided. The process comprises adding an amine compound selected from the group consisting of a) alkanolamines, b) aminocarboxylic acids and c) oligopeptides to a surfactant comprised of a member selected from the group consisting of nonionic and anionic surfactants. The amine compound is preferably selected from the group consisting of a) an alkanolamine containing 2 to 15 carbon atoms, b) an aminocarboxylic acid containing 2 to 8 carbon atoms, and c) an oligopeptide with an average molecular weight of 500 to 5000. The nonionic and anionic surfactants preferably contain 1 to 100 ethylene oxide units in the form of at least one polyethylene glycol chain. The amine compound is preferably added in a quantity of 50 to 6000 ppm, based on active substance of said surfactant.
The present invention discloses a compound of an Asiatic side local membrane forming gel, which comprises the components of the following weight percentages comprising 0.5 percentage to 7 percentage of alkyl cellulose , 1 percentage to 10 percentage of etherifying agent , 0.5 percentage to 5 percentage of cross linking agent,70 percentage to 90 percentage of dissolvent, 0.5 percentage to 10 percentage of Asiatic side . The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is C<SUB>n</SUB>H<SUB>2n+2-m-l</SUB>(OH)<SUB>m</SUB>(COOH)<SUB>l</SUB>. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. 1 is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the Asiatic side local membrane forming gel is applied for promoting the wound healing and reducing the cicatrisation. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of formulations of the Aiaticoside in the present technique, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has properties of long maintenance time and slow releasing of the medicine.
The present disclosure generally relates to preservation and delivery of a bioactive composition to a biological subject. In some embodiments, the bioactive composition include bioactives of at least one of microbes, cells, tissue, vaccines, probiotics, antibiotics, vitamins, or mRNA. Some embodiments include preserving the bioactive composition using vitrification of the bioactive composition in a vitrifying mixture of intrinsically disordered proteins and saccharides. The vitrified bioactive composition is configured to release the bioactive composition from the vitrifying mixture. Some embodiments include administering the vitrified bioactive composition to the biological subject, such that the administering includes applying the vitrified bioactive composition to a microbiome of the biological subject. Some embodiments may further include providing an enteric encapsulation of the vitrified bioactive composition that is configured to protect the vitrified bioactive composition from a first set of environmental conditions, but release the vitrified bioactive composition in a second set of environmental conditions.
OBJECTIVES: To identify and analyse the different types and frequencies of morphological pattern in endometrial biopsies along with their associated diagnoses across different age groups.
METHODS: The cross-sectional study was conducted at the Histopathology Section of the Dow Diagnostics Reference and Research Laboratory, Dow University Health Sciences, Karachi, from October 2022 to October 2023. Data was obtained from pre-existing medical record of samples of endometrial biopsies. Open Epi sample size calculator is used for the estimation of sample size. The patients were divided into two aged-based groups; reproductive age ≤45 years in group 1 and postmenopause age ≥46 years in group 2. The histological diagnosis was made by a consultant histopathologist.
RESULTS: Of the 430 endometrial biopsies 222(51.6%) were in group 1 and 208(48.4%) were in group 2. In both groups, the most common finding was polyps 271(63%). Malignant changes were found in 12(5.7%) group 2 cases compared to 4(1.8%) group 1 cases.
CONCLUSIONS: The most common endometrial lesion in both age groups was endometrial polyp. Malignant changes were seen more in postmenopausal women compared to those in the reproductive age group.
The present disclosure relates to a system for detecting occlusion of an intravenous catheter. The technical problem to be solved in one aspect of the present invention is to detect the blockage of an intravenous catheter. A system for detecting occlusion of an intravenous catheter may include a housing that may include a distal end configured to be coupled to a proximal end of a catheter adapter and a lumen forming a fluid pathway. The system may also include a wave transmitter, a transducer disposed within the fluid pathway, a processor coupled to the transducer, and an indicator unit coupled to the processor. The wave transmitter may transmit energy waves along the length of the intravenous catheter of the catheter adapter. The processor may receive an electrical signal corresponding to a portion of the energy wave reflected back from the intravenous catheter, determine a difference between the electrical signal and the baseline signal. In response to the difference between the electrical signal and the baseline signal satisfying a threshold, the indicator unit may alert a user. The technical effect of an aspect of the present invention is to provide a system for detecting catheter occlusion.
Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.
The present invention discloses an oil soluble O-chitosan derivative, the preparation thereof and the application thereof, which belongs to the technology of the preparation and the application of chitosan derivatives. The oil soluble O-chitosan derivative uses chitosan as a raw material to synthesize derivatives substitutive for ring carbon 6-OH of the chitosan, and the synthesized derivatives comprise O-9'-octadecanoic acid chitosan and O-oleoyl chitosan. The preparation method comprises: N-phthaloyl chitosan, oleoyl chloride, oleic acid and an addition product of hydrogen chloride react in a medium of isopropyl alcohol so as to obtain the oil soluble O-chitosan derivative. When animal food in which 2.5 to 7.5 wt% of the oil soluble O-chitosan derivative is added is used to feed rats, the oil soluble O-chitosan derivative has obvious function for treating and preventing the obesity of rats. Weight losing products of the chitosan of the present invention have the advantages of naturalness, no poison, obvious weight losing effect, no side effect to human bodies, etc. The oil soluble O-chitosan derivative not only can be used for treating obesity, but also can be used for preventing obesity.
Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.
The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
BACKGROUND: Sleep disorders are prevalent among patients with Alzheimer's disease (AD), and the APOE ε4 genotype is a key genetic risk factor for sporadic AD. However, the combined effect of the genotype and sleep disorders on cognitive decline remains uncertain.
METHODS: A total of 972 participants were drawn from the SILCODE cohort, comprising 655 without the ε4 allele (APOE-) and 317 with ε4 allele (APOE+). Data were collected, including neuropsychological assessments, sleep measurements, plasma biomarkers, and PET imaging. A Sleep Composite Index (SCI) was created, categorizing participants into high risk (Sleep+) and low risk (Sleep-).
RESULTS: Significant predictions of dementia risk associated with plasma p-tau181, neurofilament light chain (NfL), and SCI. Individuals with both Sleep+ and APOE+ had a higher risk of dementia compared to those with Sleep-. The Sleep+/APOE+ group had higher plasma NfL levels than the Sleep-/APOE- group. Similar trends emerged in plasma NfL levels among the Aβ PET-positive subgroup. Plasma NfL levels explained 23% of the relationship between SCI and cognitive impairment.
CONCLUSION: Our study highlights sleep disorder was associated with cognitive decline, with plasma NfL playing a partial mediating role. These findings explain how sleep disorders affect cognitive function and emphasize the importance of healthy sleep for older adults.
The invention concerns human lipoprotein 105 containing cytochrome C structural domain and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes human lipoprotein 105 containing cytochrome C structural domain.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic topical composition, having safe, effective and versatile action mechanism and achieving medication compliance of a patient.  <P>SOLUTION: A therapeutic composition for treating skin conditions and dermatoses is provided. The treatable skin conditions and dermatoses include acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, optical aging and actinic keratosis, and eczema; but are not limited thereto. The therapeutic compositions indicated herein are sponge species, more specifically, a freshwater sponge. One of the embodiment originates in Spongilla species, and is prescribed together with a pharmaceutically acceptable vehicle.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Innovations in biomedicine and recombinant protein technology show promising advances for the regeneration of advanced alveolar defects. Recombinant growth factors and biologics encourage minimally invasive procedures with improved clinical outcomes/healing times in complex oral surgery procedures. Recombinant human bone morphogenic protein-2 (rhBMP-2) is a morphogen that is a well-known regulator of bone formation1 and has been widely studied for bone reconstructive treatments.2-6 RhBMP-2 is currently commercially available and loaded on an absorbable collagen sponge (ACS). This recombinant growth factor has been approved by the US Food and Drug Administration as an alternative to autogenous bone grafting in sinus augmentation and localized alveolar ridge augmentation for defects associated with extraction sockets. It is also used off-label for vertical bone augmentation. However, there are limitations of the ACS as a carrier because it is compressible and does not ideally support soft tissues to maintain space for osteogenesis to occur. Furthermore, the release kinetics of rhBMP-2 in a standardized in vitro environment from its ACS carrier are unknown and it is further unknown how such release would compare to the use of other carriers. Subcutaneous implantation in rats and implantation at orthotropic sites in rats and rabbits has also revealed that rhBMP-2-loaded ACS has a release of rhBMP-2 over 21 days with a half-life of 2 days. The use of an alternative delivery system may retain and sequester rhBMPs at the target site and extend its growth factor release over time. This may be clinically relevant as prolonging tissue exposure to an osteoinductive growth factor like rhBMP-2 could extend the period of osteoblastic bone deposition and improve repair at regenerative sites. E-PRF as an autologous carrier for rhBMP-2 may be advantageous based on its resorption properties of up to 4-6 months, as well as its ability to support the healing process due to the slow and gradual release of several growth factors including, PDGF-AA, PDGF-BB, TGF- β1,VEGF, IGF, and EGF. This study aims to quantify the release of rhBMP-2 over a 120 day period with the use of a novel delivery system, E-PRF.